The new medicine can become hope for thousand women with hereditary cancer diseases of a breast or ovaries. Research has shown, that this medicine considerably reduces the sizes of tumours at patients at final stages of illness.
Scientists from Royal college in London have found out, that new medicine attacks the cancer cells which formation has been caused by the genetic reasons. These cause "cancer genes" only in one Great Britain on 1 500 cases of a cancer of a breast, and also every tenth case of a cancer of ovaries.

The given researches are published in authoritative scientific magazine The Lancet. They show, that approximately at 40 % of patients with a cancer of a breast and at 30 % of ovaries sick of a cancer after a therapy course observed reduction of tumours. Besides, their development has been stopped, at least, for six months.

All participants of research prior to the beginning of Olaparib therapy passed through standard treatment in the form of chemotherapy which any more did not give visible clinical effects. At all patients the final stage of a cancer which are considered as the terminal has been fixed. It does opening of the British scientists especially appreciable as now the medicine cannot offer a little effective medicines for a final stage of a cancer of a breast and ovaries.
Meanwhile Olaparib passes through a stage of clinical researches, the preparation did not leave in wide sale. Experts consider this agent as one of the most perspective preparations developed now by a science.